PMID- 31188058
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20200702
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 35
IP  - 11
DP  - 2019 Nov
TI  - Side effects from acute myeloid leukemia treatment: results from a national 
      survey.
PG  - 1965-1970
LID - 10.1080/03007995.2019.1631149 [doi]
AB  - Objective: Acute myeloid leukemia (AML) is experiencing a therapeutic renaissance 
      due to the heightened biomedical understanding of AML and patient-focused drug 
      development (PFDD). Many AML patients now live long-term with the side effects of 
      treatment. This study documents the prevalence and severity of AML 
      treatment-related side effects. Methods: A national cross-sectional survey 
      designed with the Leukemia & Lymphoma Society assessed patients' experiences with 
      short-term (nausea/vomiting, diarrhea, hair loss, mouth sores, infection, rash) 
      and long-term (organ dysfunction, chemobrain, fatigue, neuropathy) treatment side 
      effects. Patient and caregiver participants rated side effect severity 
      (none-severe). Results: Survey participants (n = 1182) were mostly female (65%), 
      AML patients (76%), and had undergone chemotherapy (94%). Eighty-seven per cent 
      of participants reported severe short-term effects, and 33% reported severe 
      long-term effects of treatment. Only 11% of respondents did not have any severe 
      effects. Hair loss and fatigue were the most common severe short- and long-term 
      side effects (78%, 33%). There was a moderate correlation between having short- 
      and long-term adverse effects (r = 0.41, p < 0.001). Caregivers were more likely 
      than patients to report severe organ dysfunction, fatigue, and neuropathy 
      (p-values < 0.05). Conclusions: Survivors experience a high burden of side 
      effects from AML treatments highlighting the need for the development of less 
      toxic therapies. Differences in patients' and caregivers' experiences illustrate 
      the importance of sampling from diverse sources to understand the full burden of 
      AML treatment, and the need for less toxic drugs. This study informs patients, 
      patient-advocacy groups, clinicians, and regulators about AML treatment burdens 
      and provides the community with information to inform PFDD.
FAU - Crossnohere, Norah L
AU  - Crossnohere NL
AUID- ORCID: 0000-0002-2811-1330
AD  - Department of Health, Behavior, and Society, The Johns Hopkins Bloomberg School 
      of Public Health , Baltimore , MD , USA.
AD  - Department of Biomedical Informatics, The Ohio State University Wexner Medical 
      Center , Columbus , OH , USA.
FAU - Richardson, Daniel R
AU  - Richardson DR
AD  - Division of Hematology/Oncology, Department of Medicine, University of North 
      Carolina , Chapel Hill , NC , USA.
FAU - Reinhart, Crystal
AU  - Reinhart C
AD  - School of Social Work, University of Illinois at Urbana-Champaign , Urbana , IL , 
      USA.
FAU - O'Donoghue, Bernadette
AU  - O'Donoghue B
AD  - The Leukemia & Lymphoma Society , Rye Brook , NY , USA.
FAU - Love, Susan M
AU  - Love SM
AD  - Dr. Susan Love Research Foundation , Encino , CA , USA.
FAU - Smith, B Douglas
AU  - Smith BD
AD  - Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, 
      The Johns Hopkins School of Medicine , Baltimore , MD , USA.
FAU - Bridges, John F P
AU  - Bridges JFP
AD  - Department of Health, Behavior, and Society, The Johns Hopkins Bloomberg School 
      of Public Health , Baltimore , MD , USA.
AD  - Department of Biomedical Informatics, The Ohio State University Wexner Medical 
      Center , Columbus , OH , USA.
LA  - eng
GR  - T32 HS000032/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190626
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alopecia/chemically induced
MH  - Antineoplastic Agents/*adverse effects
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - Adverse effects
OT  - Long-term adverse effects
OT  - Patient-focused drug development
OT  - Quality-of-life: Treatment outcome
EDAT- 2019/06/13 06:00
MHDA- 2020/07/03 06:00
CRDT- 2019/06/13 06:00
PHST- 2019/06/13 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2019/06/13 06:00 [entrez]
AID - 10.1080/03007995.2019.1631149 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2019 Nov;35(11):1965-1970. doi: 10.1080/03007995.2019.1631149. 
      Epub 2019 Jun 26.